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The question implicit in my title was explicitly framed by
Alan Guttmacher and colleagues1 in an article entitled
“Genomic Medicine: Who Will Practice It?” While this
question is a general one, my particular concern is with
what the roles of medical genetics and medical geneticists
will be in what is being referred to as genomic medicine.
To answer these questions, it is necessary to deﬁne what
we mean by “medical genetics and medical geneticists”
and by “genomic medicine.” Although this might appear
to be a semantic exercise, that is not my intention. Rather,
if we are to look at the future role of medical genetics in
the practice of medicine, I believe that we really need to
understand what we are talking about. I shall start with
medical genetics and medical geneticists.
Medical Genetics
The term “medical genetics” has been variously deﬁned
as the science of human biological variation as it relates
to health and disease2; the study of the etiology, patho-
genesis, and natural history of diseases and disorders that
are at least partially genetic in origin3; and the application
of genetics to medicine4 or to medical practice.5 Further-
more, medical genetics services have been deﬁned as “an
integrated clinical and laboratory service provided for
those with [or] concerned about a disorder with a signif-
icant genetic component and their families (this includes
inherited and sporadic genetic disorders)….”6 These def-
initions embody the tension between medical genetics as
a science and as a clinical area or specialty of medicine,
but, clearly, medical genetics is really both.
However it is deﬁned, medical genetics initially grew up
within human genetics, with an agenda consisting largely
of research and only a modest clinical component. Many
of the founders of the ﬁeld, or at least of the American
version of it—Arno Motulsky, Victor McKusick, James
Neel, Kurt Hirschhorn—were internists by training, as
were many of their early disciples. However, with the pro-
gress in medical genetics that was made possible by the
conceptual and technological advances of the 1950s and
60s—particularly in cytogenetics and biochemical genet-
ics7—and with the growth of dysmorphology in the 1960s
and 70s, medical geneticists became more clinical and
more pediatric in orientation. This shift was of great con-
cern to at least some medical geneticists, and in his 1977
Presidential Address to the American Society of Human
Genetics, Motulsky issued the following warning:
Medical geneticists need to broaden their ﬁelds of in-
terest to encompass other ﬁelds than those of pediatric
interest alone. We need to attract more basic scientists.
Our ﬁeld is evolving from a largely research oriented
science to a service-oriented specialty. This logical de-
velopment is a sign of increasing maturity and makes
available to the public the results of our research. The
resulting stresses and strains need careful watching to
prevent their slowing the momentum of our science….8
Despite this warning, the demands of clinical service cre-
ated increasing inroads into the more basic research en-
deavors of medical geneticists, and medical genetics rap-
idly became virtually synonymous with clinical genetics
and pediatrics.
This change in identity was carved into stone by a series
of events that began in 1980, when the American Society
of Human Genetics spun off the American Board of Med-
ical Genetics to certify medical geneticists and genetic
counselors and to accredit training programs (ﬁg. 1). Both
clinical and laboratory-based medical geneticists were cer-
tiﬁed, with those who were physicians being certiﬁed in
clinical genetics. The AmericanCollege ofMedicalGenetics
was created about 10 years later, and this relieved the So-
ciety of responsibilities to clinical genetics and geneticists
and permitted it to return to the research and education
agenda that was and still is its principal concern. The full
legitimization of medical genetics as a clinical specialty
took place in 1991, when the American Board of Medical
Genetics was admitted, without the genetic counselors, to
the American Board of Medical Specialties. Medical Ge-
netics thus became the 24th primary specialty of medi-
cine, and the Residency ReviewCommittee (RRC) forMed-
ical Genetics, which accredits clinical medical genetics
training programs, was formed the following year under
the aegis of the Accreditation Council for Graduate Med-
ical Education.
Medical genetics now had in place the four pillars (ﬁg.
2) of a conventional medical specialty: a research society,
a college (or academy), a certifying board, and an RRC—
each ofﬁcially independent of the other, but in reality
highly interrelated. However, by its very success in be-
coming institutionalized, medical genetics deﬁned itself
principally in terms of its clinical content—which is really
clinical genetics—and not of its science. This might give
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Figure 1. Pedigree of the organizations that constitute the med-
ical genetics establishment.
Figure 2. Quadripartite structure of the medical genetics
ediﬁce.
the impression that the fortunes of medical genetics as a
scientiﬁc discipline rise and fall with the success of med-
ical genetics as a clinical specialty, but this is not really
the situation. The science of medical genetics, the appli-
cation of human genetics to medicine, is in fact more
robust and thriving than ever and has truly entered the
mainstream ofmedical science. Themeetings of the Amer-
ican Society of Human Genetics, at which the science is
presented, are very well attended, and the pages of the
American Journal of Human Genetics and of many other
journals, where it is published, testify to the continued
and increasing vigor of the ﬁeld. What has changed, how-
ever, is that much of medical genetics research is now
being done by physicians and scientists who, while using
the tools and principles of genetics to study human ge-
netic diseases, do not consider themselves to be medical
geneticists or, for the most part, even human geneticists.
Fortunately, as far as the science is concerned, this is really
of no great consequence. Medical genetics research is be-
ing done and continues to contribute to medicine, ge-
nomic or otherwise, and this is what is important.
Medical Geneticists
Turning again to the clinical side of medical genetics, it
is instructive to view how it is currently formulated. This
is perhaps best summarized in the Program Requirements
of the RRC for Medical Genetics, which describe what
medical geneticists do and specify how medical genetics
training programs are to operate.
Clinical medical geneticists are physicians who pro-
vide comprehensive diagnostic, management, and ge-
netic counseling services for patients with genetic, or
possibly genetic, disorders…[and] plan and coordinate
large-scale screening programs….Clinical medical ge-
neticists are able to (a) diagnose and manage genetic
disorders; (b) provide patient and family counseling; (c)
use their knowledge of heterogeneity, variability, and
natural history of genetic disorders in patient-care de-
cision making; (d) elicit and interpret individual and
family medical histories; (e) interpret clinical genetic
and specialized laboratory testing information; (f) ex-
plain the causes and natural history of genetic disorders
and genetic risk assessment; and (g) interact with other
health-care professionals in the provision of services for
patients with genetically inﬂuenced disorders.
[Training] Programs must provide…education in the
basic sciences and clinical areas pertinent to medical
genetics, including mendelian genetics, cytogenetics,
diagnosis and treatment of inborn errors ofmetabolism,
molecular diagnosis, syndrome identiﬁcation and dys-
morphology, teratology, reproductive genetics, con-
genital malformations, multifactorial disorders, mental
retardation and developmental disabilities, genetic
screening, social and ethical issues in medical genetics,
genetic counseling, and quantitative human genetics.9
These descriptions and speciﬁcations are, of course, quite
broad, and not every medical geneticist is expert in or
practices all of the components listed. In fact, whether
formally or informally deﬁned, there are areas of special-
ization within clinical genetics, the three most important
being dysmorphology, metabolic diseases, and prenatal di-
agnosis. Nevertheless, all medical geneticists are expected
to have a general knowledge of all of the areas speciﬁed
in the program requirements.
Genomic Medicine
With this understanding of what medical geneticists are
being trained to do, I turn now to consider what is
meant by “genomic medicine” (or by the more or less
interchangeable terms “genetic medicine” and “molecular
medicine”). Below are two deﬁnitions.
In the description of a course on the subject, the Har-
vard-MIT Division of Health Sciences & Technology de-
ﬁnes genomic medicine as
…the use of industrialized methods of data acquisi-
tion and analysis to improve medical care, including
436 The American Journal of Human Genetics Volume 79 September 2006 www.ajhg.org
prognostics, diagnostics, preventive intervention, ther-
apeutic selection, and individualized treatment based
on the complex interaction between inherited and ac-
quired elements of human variation.Genomicmedicine
will have a transformative role in healthcare, whose em-
phasis can be anticipated to dramatically shift from dis-
ease treatment to health maintenance.10
In a similar vein, Willard deﬁned genomic medicine as
the application of the science of genomes, as opposed to
genes, to the practice of medicine. As such,
It goes well beyond the traditional boundaries of ge-
netics in medicine, as articulated by the medical spe-
cialty of Medical Genetics…that branch of human ge-
netics that concerns itself with disease….Genomic
medicine…is an approach that will build on the com-
prehensive nature of the genome sciences….As a clinical
paradigm, genomic medicine will provide global, com-
prehensive, and multidimensional treatment and man-
agement strategies based on the science now emerging
from the study of genomes.11
He outlined the purpose for all of this in the following
manner:
The prospect of examining a person’s entire genome
(or at least a large fraction of it) in order to make in-
dividualized risk predictions and treatment decisions is
a tantalizing one….Having access to the entire human
sequence is a necessary but insufﬁcient prerequisite for
genomic medicine. What is equally important is having
the technology at hand to reliably visualize individual
genomes (and their derivatives, the transcriptome, pro-
teome and metabolome) for health information that, in
combination with clinical data, can contribute to as-
sessment of individual risks and guide clinical manage-
ment and decision-making. [This makes] the prospect
for developing truly individualized care…even more
real.12
These two deﬁnitions are quite broad. They certainly
encompass the “medicine” side of “genomic medicine,”
but there is also emphasis in the ﬁrst deﬁnition on “in-
dustrializedmethods of data acquisition and analysis” and
in the second on “global, comprehensive, and multidi-
mensional…strategies” and “the technology to reliably vi-
sualize individual genomes.” It is clear that what is really
new in genomic medicine is the application of genomic
technology on a large scale to virtually every problem of
medicine. We might call this the “process” of genomic
medicine. However, these deﬁnitions also make it clear
that the intent of genomic medicine is what has been var-
iously described as preventive intervention, individual-
ized treatment, prospective medicine,13 or personalized
medicine14 and medicines (referring, of course, to phar-
macogenetics15). Weston and Hood16 combine all of these
together as the 3 Ps: predictive, preventive, and personalized
medicine.
Key to all of this, of course, will be risk assessment based
on testing, and there are, indeed, many forms of testing
already in use and being developed—biochemical, genetic,
genomic, proteomic, metabolomic, and pharmacogenetic
(or pharmacogenomic). From the point of view of public
perception, testing is where things are headed when we
talk about genomic medicine. Indeed, as I have written
elsewhere,17 there appears to be a pervasive belief in both
scientiﬁc and public circles that genetic testing or proﬁling
is going to be the cornerstone of much, if not all, of ge-
nomic medicine—in fact, all of medicine—in the future.
In that article, I outlined the debate swirling around this
notion, and I will not repeat that entire discussion here.
However, a few points are worth repeating: genetic risk
assessment will attain sufﬁcient predictive power to be of
use if—and only if—analyses ofmany genetic loci are com-
bined with evaluations of nongenetic lifestyle and envi-
ronmental factors. The results of such risk assessmentswill
not be absolutely deﬁnitive. The information will be prob-
abilistic, and we shall always be dealing with estimates of
risk, not predictions of certain outcomes. That risk as-
sessment or proﬁling can be done does not mean that it
actually will or, indeed, should be done. This will ulti-
mately be determined by whether testing really offers
more than currently available forms of risk assessment in
terms of predictive power and securing compliance—in
other words, by whether it will have greater clinical utility
and would enhance a person’s motivation to comply with
recommendations for therapy and changes in lifestyle.
Medical Geneticists and Genomic Medicine
I have no doubt that medical genetics and medical ge-
neticists will play an important role in the development
of genomic medicine, however that development ulti-
mately plays out. But what role will clinical medical ge-
neticists play in its implementation and applications? (I
focus here on clinical geneticists because laboratory-based
geneticists, by virtue of what they do, will be intimately
involved in testing, unless the process becomes so indus-
trialized as to exclude even them—a scenario that is cer-
tainly not impossible to imagine.) It has been said, and
rightly, that genomic medicine will transcend the current
boundaries of medical genetics11 and will be applicable to
the health care of the many or all rather than just the
few.1,18 Whether, given the current inequities in the
health-care system, the latter situationwill ever be realized
in full19 will have to await future determination. However,
it is certainly true that genomic medicine, as deﬁned ear-
lier, is a far cry from clinical medical genetics, as currently
conceptualized in the Program Requirements of the RRC
for Medical Genetics presented earlier. The question is
what this means for the future of clinicalmedical genetics.
This and related issues are currently the subject of active
debate in the ofﬁcial organizations concerned with med-
ical genetics,20 and, at this point, I can only give my own
view of the situation.
The easiest thing, of course, would be for clinical med-
ical geneticists to continue to do what they have been
doing for the past 35 years or so. They could maintain the
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status quo and continue to function as experts on Men-
delian disorders, dysmorphology, chromosomal disorders,
inherited metabolic diseases, and perhaps the genetic as-
pects of diseases, such as breast and ovarian cancer, that
are caused by high-penetrance susceptibility genes, with
the degree of emphasis on some versus others being a
matter of personal preferences and/or institutional re-
quirements. In fact, I believe that it will certainly be nec-
essary for clinical geneticists, at least some proportion of
them, to continue to do many of these things—but I also
think that they will need to be able to do even more in
the future. What is lacking from this approach, and from
the Program Requirements of the RRC, is a concern for
and involvement with the wide range of conditions re-
ferred to as the “common adult diseases” or “complex
traits,” and it just these disorders that are the targets of
genomic medicine. Although they are generally not Men-
delian in origin, these conditions have their origins in the
interactions of genetic factors (some or many, depending
on the particular condition) with one another and with
the environment. Their genetics is, therefore, truly poly-
genic and multifactorial—but it is still genetics nonethe-
less, and the fact that genomic tools will make it possible
to acquire the knowledge required and to carry out the
necessary testing procedures, whether genomewide or
otherwise, does not make the approach any less genetic.
The issue, then, is whether medical geneticists acting in
their clinical roles can and should be part of genomicmed-
icine. With regard to the can, I do not believe that the
training being provided at present to clinical genetics
residents is, in most instances, sufﬁcient to allow this to
happen.21 What is lacking is a greater and more intensive
instruction in population genetics and epidemiology, ge-
netic and otherwise; pharmacogenetics; bioinformatics;
the principles of risk assessment; and the common adult
diseases and complex traits. There is no question in my
mind that training programs can be reformulated to per-
mit this to occur, and discussions about how this might
be done are currently under way in organizations within
medical genetics. So, if we assume that they would have
the knowledge to do so, should the clinical geneticists get
involved with genomic medicine?
It has been argued in several quarters that the principal
role for the realization of the promise of genomic medi-
cine will belong to primary-care physicians and other
health-care personnel rather than to medical geneticists1
(for fuller discussion, see Epstein17). Although the therapy,
preventive and otherwise, of common/adult/complex dis-
eases will (and should, in most instances) remain ﬁrmly
in the domain of primary-care physicians and relevant
specialists, I think it unlikely that these physicians will be
able to handle the complexities of comprehensive genetic
testing and risk assessment alone, unless the ways in
which medicine is practiced are drastically changed. They
just won’t have the time or expertise to do so. It might
be argued that all of the testing and risk assessment that
genomic medicine embodies will be a highly automated
operation, perhaps even a largely online operation. In this
model, the testing will, of course, be completely auto-
mated, and only a blood sample will be required. The
acquisition of historical, demographic, and environmen-
tal information from the interested person him- or herself
will be computer-based, as will the calculation of risks and
formulation of recommendations. All in all, it will be a
black-box procedure, but both the physician and the pa-
tient him- or herself will still have to deal with the prob-
abilistic nature of the results. As experience with risk as-
sessment for breast and ovarian cancer has already taught
us, they will need to have knowledgeable people to turn
to.
The major issues for geneticists and nongeneticists alike
are time, knowledge, and money. Given the present or-
ganization of medical services, especially in the United
States, nongeneticist primary-care providers and special-
ists will have very little time to take on the broad respon-
sibilities of personal risk assessment and management.
The danger is that these functions will become somewhat
mindless operations driven by commercial testing com-
panies and passed down to less-qualiﬁed personnel. Fur-
thermore, most primary-care providers and specialists do
not really have the knowledge base that will be required
to permit meaningful assessments to be made. Although
efforts are being made by professional organizations, such
as the American Academy of Family Practice and the
American College of Physicians, to educate their members
about genetics, fundamental changes will have to bemade
to integrate genetics fully into medical school curricula
and residency training programs if the necessary concepts
and knowledge base are to be inculcated. Despite much
talk, this has been slow to evolve in medical training, and
it has not yet even begun to occur in a serious way at the
residency level, where the attitudes that will inﬂuence
practice for the rest of life are really developed. And, with
regard to money, there will have to be a major shift in
how medical services are paid for if physicians are to be
adequately reimbursed for the time that meaningful risk
assessments and preventive interventionswill require. The
same impediments becoming involved in genomic med-
icine—time, knowledge, and money—also apply to med-
ical geneticists.
So, why should medical geneticists get involved? Why
don’t medical geneticists just continue to do what they
are doing? For me, the answer is quite straightforward—
in fact, there are two answers. The ﬁrst is that I just can’t
imagine medical geneticists not being intimately involved
in the expanded role of genetics in medicine. Genomic
medicine in some form is ultimately going to happen—it
has already begun—and medical geneticists ought to and
need to be part of it. The second answer to why they
should is that it will be critical to the survival of medical
genetics as a vital and exciting profession. How ironic it
would be if medical genetics, possibly the last of the pri-
mary clinical specialties of medicine to be formally rec-
ognized, were to wither away just at the time that it is
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being ﬁnally acknowledged that genetics does have a ma-
jor part to play in all aspects of medicine and health.
When they issued their call to open arms—that is, for
the medical geneticists to open their arms and bring the
primary-care providers into the genetics fold—Gutt-
macher et al.1 asserted that the expansion of nongenetic
specialist providers’ use of genetics “will not relegate ge-
netic specialists to the dustbin of medical history, but in-
stead will redeﬁne their roles.” Although this was intended
to be reassuring, the phrase “dustbin of medical history”
certainly conjured up a terrible image. Nevertheless, I
think that we have now truly reached the point of the
redeﬁnition of roles of which they wrote. If the needs of
the general public are to be properly served, primary-care
physicians, nongeneticist specialists, and/or testing labo-
ratories will not be able to go it alone in the era of wide-
scale presymptomatic risk assessment and preventive
management and pharmacogenetic testing when it even-
tually comes. Clinical geneticists and genetic counselors
will have to be part of the mix. There will be enough for
everyone to do, once they understand what is required.
If medical geneticists remember their scientiﬁc heritage
and become less passive, broaden their perspectives, ex-
pand their training, and interact more closely with pri-
mary-care providers and other specialists,medical genetics
will assuredly become an essential part of the genomic
medicine of the 21st century. The real task then will be
to organize the health-care system to facilitate rather than
hinder the integration of medical genetics into genomic
medicine.
CHARLES J. EPSTEIN
Department of Pediatrics and Center for Human
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